Niagen Bioscience Inc (NAGE)

Profitable, cash-rich small-cap with strong gross margins and a demonstrated turnaround in FY2024–FY2025, trading at a reasonable multiple (TTM P/E ~15; EV/EBITDA ~10). Recent quarters show softer sales and lower profits as spending increases, and the large FY2025 inventory build adds execution risk. Attractive on financial strength and valuation, but expect volatility and monitor near-term demand and regulatory/supplier concentration closely.

Absent setup on a quiet catalyst calendar: no forward-dated driver within 30 days (only conference appearances; Q3 earnings unannounced and beyond horizon) and no in-window event with net-positive market reception; sentiment delta determinate cooling from a mildly positive baseline (+0.21, 7 items) to a neutral thin in-window tape (2 scorable items, low confidence); Red-Flag Screen clean, no cap applied; absent-setup floor applies.

NAGE is basing just above its 52-week low (2.87) but below all key averages (SMA20 3.11, SMA50 3.19, SMA200 4.47) with negative MACD (-0.06 line below -0.05 signal, both under zero), trendless ADX (12.18), and weak-neutral momentum (RSI 44.05, Williams %R -68.97). The two-week 2.95-3.05 range shows no confirmed bullish trigger. Independently of the chart, the qualitative floor (qualitativeScore 2 < 3) is a hard block and liquidity fails both the $5M 20-day floor (~$1.17M) and the $1.5M recent-liquidity floor (~$1.04M); technicalScore 2 (neutral/weak bearish, bounce-only at best).